PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 30171201-4 2019 We showed that AKBA dose-dependently inhibited cell proliferation and induced cell apoptosis in docetaxel-resistant PC3/Doc cells; its IC50 value in anti-proliferation was ~17 muM. Docetaxel 96-105 chromobox 8 Homo sapiens 116-119 30993586-10 2020 In addition, the combination of apigenin treatment and MK silencing showed better outcomes on the anticancer efficacy of docetaxel in CD44+CD133+ PC3 cells. Docetaxel 121-130 chromobox 8 Homo sapiens 146-149 31834633-12 2020 Salinomycin decreased the CD24- /CD44high population in both docetaxel-sensitive PC3 and docetaxel-resistant (DR) PC3-DR. Docetaxel 61-70 chromobox 8 Homo sapiens 81-84 31834633-12 2020 Salinomycin decreased the CD24- /CD44high population in both docetaxel-sensitive PC3 and docetaxel-resistant (DR) PC3-DR. Docetaxel 89-98 chromobox 8 Homo sapiens 114-117 29187435-4 2017 MATERIALS AND METHODS: MTS assays were used to determine the effect of metformin-docetaxel treatment on PC3 and DU145 cell viability. Docetaxel 81-90 chromobox 8 Homo sapiens 104-107 30519360-12 2018 Results: The cytotoxic effects of DOC were synergistically enhanced by SDA when the two were added to DU145 and PC3 cell cultures. Docetaxel 34-37 chromobox 8 Homo sapiens 112-115 30100995-4 2018 PC3 and DU145 cells were selected for DTX resistance and this phenotype was validated by immunoblotting using DTX resistance markers (e.g. clusterin, ABCB1/P-gp, and LEDGF/p75). Docetaxel 38-41 chromobox 8 Homo sapiens 0-3 30100995-4 2018 PC3 and DU145 cells were selected for DTX resistance and this phenotype was validated by immunoblotting using DTX resistance markers (e.g. clusterin, ABCB1/P-gp, and LEDGF/p75). Docetaxel 110-113 chromobox 8 Homo sapiens 0-3 29314097-6 2018 RESULTS: Docetaxel and VS-6063 co-treatment caused a greater decrease in the viability of docetaxel-resistant CRPC cells, and a greater inhibition in PC3 xenograft growth compared to either monotherapy. Docetaxel 9-18 chromobox 8 Homo sapiens 150-153 29187435-7 2017 RESULTS: Metformin-docetaxel treatment significantly reduced PC3 cell viability. Docetaxel 19-28 chromobox 8 Homo sapiens 61-64 28533751-5 2017 The ability of the docetaxel-loaded nanoparticles to induce cellular death in different prostate (human LnCap and PC3) and glioblastoma (human U87 and rat C6) cells was also explored. Docetaxel 19-28 chromobox 8 Homo sapiens 114-117 28758908-6 2017 The aim of this work was to analyze the enhancement of the anticancer effect of TRAIL by paclitaxel, cabazitaxel and docetaxel in the whole population of PC3 and DU145 prostate cancer cells, but also in CD44+/CD24- prostate cancer stem cells. Docetaxel 117-126 chromobox 8 Homo sapiens 154-157 27542265-5 2016 We found that docetaxel-resistant PC3 cells (PC3-DR) acquire a pro-invasive behavior undergoing epithelial-to-mesenchymal-transition (EMT) and a decrease of both intracellular ROS and cell growth. Docetaxel 14-23 chromobox 8 Homo sapiens 34-37 28212536-6 2017 Silencing LEDGF/p75 effectively sensitized taxane-resistant PC3 and DU145 cells to DTX and CBZ, as evidenced by a significant decrease in their clonogenic potential. Docetaxel 83-86 chromobox 8 Homo sapiens 60-63 27542265-5 2016 We found that docetaxel-resistant PC3 cells (PC3-DR) acquire a pro-invasive behavior undergoing epithelial-to-mesenchymal-transition (EMT) and a decrease of both intracellular ROS and cell growth. Docetaxel 14-23 chromobox 8 Homo sapiens 45-48 25708950-0 2015 Paradoxical effects of the autophagy inhibitor 3-methyladenine on docetaxel-induced toxicity in PC-3 and LNCaP prostate cancer cells. Docetaxel 66-75 chromobox 8 Homo sapiens 96-100 26404131-0 2016 Osteopontin splice variants expression is involved on docetaxel resistance in PC3 prostate cancer cells. Docetaxel 54-63 chromobox 8 Homo sapiens 78-81 26404131-3 2016 In this report, we investigated some cellular mechanisms by which OPN splice variants could mediate PC3 prostate cancer (PCa) cell survival and growth in response to docetaxel (DXT)-induced cell death. Docetaxel 166-175 chromobox 8 Homo sapiens 100-103 25708950-5 2015 PC-3 and LNCaP cells were pre-treated with the autophagy inhibitor 3-methyladenine (5 mM) and then exposed to various concentrations (0-100 muM) of docetaxel. Docetaxel 148-157 chromobox 8 Homo sapiens 0-4 25708950-7 2015 Docetaxel produced significant toxicity in PC-3 cells but was not toxic to LNCaP cells. Docetaxel 0-9 chromobox 8 Homo sapiens 43-47 25708950-8 2015 Pre-treatment with the autophagy inhibitor, 3-methyladenine (5 mM) significantly protected PC-3 cells against docetaxel-induced cytotoxicity, increased autophagosome formation and apoptosis measured using monodansylcadaverine, annexin V and caspase-3 fluorescence, respectively. Docetaxel 110-119 chromobox 8 Homo sapiens 91-95 25333266-4 2014 PC3 cells were less sensitive to DTX than were the other two cell lines. Docetaxel 33-36 chromobox 8 Homo sapiens 0-3 25333266-6 2014 ABT-263 also enhanced the antitumor effect of DTX on a DTX-resistant PC3 variant cell line. Docetaxel 46-49 chromobox 8 Homo sapiens 69-72 25333266-6 2014 ABT-263 also enhanced the antitumor effect of DTX on a DTX-resistant PC3 variant cell line. Docetaxel 55-58 chromobox 8 Homo sapiens 69-72 23728939-4 2014 Herein we show that PC-3 human prostate cancer xenografts were sensitive to both metronomic cyclophosphamide and metronomic docetaxel, but resistant to metronomic topotecan. Docetaxel 124-133 chromobox 8 Homo sapiens 20-24 25104727-7 2014 Knocking down TR4 in PC3 cells led to a lower IC50 dose, poorer cell viability and more cell apoptosis when treated with docetaxel, whereas overexpression of TR4 in PC3 led to a higher IC50 dose, better cell viability and less cell apoptosis. Docetaxel 121-130 chromobox 8 Homo sapiens 21-24 23728939-5 2014 Conventional docetaxel was only moderately active in parental PC-3 and in metronomic cyclophosphamide resistant PC-3 tumors. Docetaxel 13-22 chromobox 8 Homo sapiens 62-66 23728939-5 2014 Conventional docetaxel was only moderately active in parental PC-3 and in metronomic cyclophosphamide resistant PC-3 tumors. Docetaxel 13-22 chromobox 8 Homo sapiens 112-116 24194567-4 2014 Using quantitative mass spectrometry-based phosphoproteomics, we identified that metastatic docetaxel-resistant prostate cancer cell lines (DU145-Rx and PC3-Rx) exhibit increased phosphorylation of focal adhesion kinase (FAK) on Y397 and Y576, in comparison with parental controls (DU145 and PC3, respectively). Docetaxel 92-101 chromobox 8 Homo sapiens 153-156 24194567-4 2014 Using quantitative mass spectrometry-based phosphoproteomics, we identified that metastatic docetaxel-resistant prostate cancer cell lines (DU145-Rx and PC3-Rx) exhibit increased phosphorylation of focal adhesion kinase (FAK) on Y397 and Y576, in comparison with parental controls (DU145 and PC3, respectively). Docetaxel 92-101 chromobox 8 Homo sapiens 292-295 24179545-5 2013 The sensitivity of the PC3 cells to docetaxel and cisplatin was significantly enhanced following treatment with AexU, resulting in a decrease in the IC50 of the two agents by ~90%. Docetaxel 36-45 chromobox 8 Homo sapiens 23-26 24405548-1 2013 OBJECTIVE: To explore the antitumor effects of 2-deoxyglucose (2-DG) plus docetaxel (Doc) on PC3 and DU145 cells and its mechanism. Docetaxel 74-83 chromobox 8 Homo sapiens 93-96 24405548-1 2013 OBJECTIVE: To explore the antitumor effects of 2-deoxyglucose (2-DG) plus docetaxel (Doc) on PC3 and DU145 cells and its mechanism. Docetaxel 85-88 chromobox 8 Homo sapiens 93-96 24405548-8 2013 The inhibition rates for PC3 proliferation at 48 h by Doc with concentrations of 0.1, 0.5, 2.5 nmol/L were 10.71%, 25.32% and 56.46% respectively. Docetaxel 54-57 chromobox 8 Homo sapiens 25-28 24405548-10 2013 The inhibition rates for PC3 cell proliferation by Doc plus 2-DG with a concentration of 1.0 g/L were 27.15%, 58.74% and 87.95% respectively and 29.53%, 59.41%, and 90.48% for DU145 respectively. Docetaxel 51-54 chromobox 8 Homo sapiens 25-28 24405548-12 2013 The apoptotic rates for PC3 and DU145 induced by Doc 0.5 nmol/L plus 2-DG 1.0 g/L at 48 h were 46.49% and 53.64% respectively. Docetaxel 49-52 chromobox 8 Homo sapiens 24-27 22996738-4 2013 METHODS: The effects of docetaxel on human DU145, PC3, LNCaP, and C4-2 prostate cancer cells were examined in cell culture, and p53 expression were analyzed by Western blot analysis. Docetaxel 24-33 chromobox 8 Homo sapiens 50-53 23192362-8 2013 Activation of EGFR expressed on MSCs by PC3-CM enhanced their capability to increase PC3 cells proliferation and to inhibit Docetaxel activity. Docetaxel 124-133 chromobox 8 Homo sapiens 40-43 22996738-6 2013 RESULTS: We found that DU145 (mutant p53) and PC3 (p53 null) cells were less sensitive than LNCaP and C4-2 cells expressing functional p53 in response to docetaxel. Docetaxel 154-163 chromobox 8 Homo sapiens 46-49 22996738-7 2013 Docetaxel treatment induces considerably higher apoptosis in LNCaP and C4-2 cells than in DU145 and PC3 cells in a dose dependent manner. Docetaxel 0-9 chromobox 8 Homo sapiens 100-103 22952424-7 2012 Furthermore, we demonstrated that AMD3100 sensitizes PC3-luc cells to docetaxel. Docetaxel 70-79 chromobox 8 Homo sapiens 53-56 21711774-11 2011 In particular, an increase of 20% of PC3 growth inhibition was determined by PLGA-PCL NPs with respect to free drug after 72 h incubation and at all tested Dtx concentration. Docetaxel 156-159 chromobox 8 Homo sapiens 37-40 22811914-3 2012 DOC showed a biphasic cytotoxicity pattern with the half maximal inhibitory concentration (IC50) at the picomolar range for PC3 (0.598 nM) and DU145 (0.469 nM), following 72 h drug exposure. Docetaxel 0-3 chromobox 8 Homo sapiens 124-127 22811914-5 2012 Strong synergy was seen when PC3 was treated with DOC at concentrations lower than its IC50 values (0.125~0.5 nM) plus DOX (2~8 times IC50). Docetaxel 50-53 chromobox 8 Homo sapiens 29-32 21645351-12 2011 Reovirus/docetaxel combined therapy led to reduced tumour growth and increased survival in a PC3 tumour bearing mouse model. Docetaxel 9-18 chromobox 8 Homo sapiens 93-96 21645351-13 2011 Microtubule stabilization was enhanced in PC3 cells treated with reovirus/docetaxel combined therapy compared to other reovirus/chemotherapy combinations. Docetaxel 74-83 chromobox 8 Homo sapiens 42-45 21549092-0 2011 Combined effect of sodium selenite and docetaxel on PC3 metastatic prostate cancer cell line. Docetaxel 39-48 chromobox 8 Homo sapiens 52-55 21549092-5 2011 Here we report the effect of docetaxel and sodium selenite combination on the PC3 prostate cancer cell line, derived from bone metastasis. Docetaxel 29-38 chromobox 8 Homo sapiens 78-81 19912186-4 2010 The growth and the sensitivity to docetaxel in PC3/sh-A were compared with those in PC3 transfected with control vector alone (PC3/C). Docetaxel 34-43 chromobox 8 Homo sapiens 47-50 21035484-2 2011 The PC3/(CIC) cells are more resistant than the PC3/(BC) cells to chemotherapeutic drugs such as docetaxel which is used to treat prostate cancer. Docetaxel 97-106 chromobox 8 Homo sapiens 4-7 21035484-2 2011 The PC3/(CIC) cells are more resistant than the PC3/(BC) cells to chemotherapeutic drugs such as docetaxel which is used to treat prostate cancer. Docetaxel 97-106 chromobox 8 Homo sapiens 48-51 20816710-5 2010 We studied the effect of increasing concentrations of free DTX or DTX-loaded micelles on growth inhibition of human breast MCF-7 and MDA-MB468 and prostate PC3 and DU145 adenocarcinoma cell lines. Docetaxel 59-62 chromobox 8 Homo sapiens 156-159 20816710-5 2010 We studied the effect of increasing concentrations of free DTX or DTX-loaded micelles on growth inhibition of human breast MCF-7 and MDA-MB468 and prostate PC3 and DU145 adenocarcinoma cell lines. Docetaxel 66-69 chromobox 8 Homo sapiens 156-159 20729074-8 2010 ELISA assays showed that DXL induced accumulation of cytoplasmic VEGF but decreased extracellular levels by 39% (MDA) and 48% (PC3). Docetaxel 25-28 chromobox 8 Homo sapiens 127-130 20551061-5 2010 In contrast, the cytotoxic microtubule inhibitor docetaxel increased glycerophosphocholine and tCho levels in PC3 cells. Docetaxel 49-58 chromobox 8 Homo sapiens 110-113 18594829-0 2008 Docetaxel and bortezomib downregulate Bcl-2 and sensitize PC-3-Bcl-2 expressing prostate cancer cells to irradiation. Docetaxel 0-9 chromobox 8 Homo sapiens 58-62 19103299-4 2009 Combination of docetaxel and zoledronic acid synergistically inhibits cell growth in PC-3 and DU-145 cells. Docetaxel 15-24 chromobox 8 Homo sapiens 85-89 19050703-3 2008 Dexamethasone also attenuated docetaxel-induced NF-kappaB and activator protein-1 transcription and reduced docetaxel-promoted expression/secretion of IL-8 and CXCL1 in PC3 and hBMECs. Docetaxel 108-117 chromobox 8 Homo sapiens 169-172 18594829-8 2008 In addition, docetaxel, bortezomib, or radiation resulted in a G2M phase arrest in PC-3-Bcl-2, whereas only docetaxel or radiation did so in PC-3-Neo cells. Docetaxel 13-22 chromobox 8 Homo sapiens 83-87 18594829-8 2008 In addition, docetaxel, bortezomib, or radiation resulted in a G2M phase arrest in PC-3-Bcl-2, whereas only docetaxel or radiation did so in PC-3-Neo cells. Docetaxel 108-117 chromobox 8 Homo sapiens 141-145 14991863-6 2004 Additive combination effects are also observed when irofulven and docetaxel were tested against PC-3 xenografts and curative activity (8/10 CR) is observed in DU-145 xenografts. Docetaxel 66-75 chromobox 8 Homo sapiens 96-100 18189232-0 2008 2-chloroadenosine modulates PAR-1 and IL-23 expression and enhances docetaxel effects on PC3 cells. Docetaxel 68-77 chromobox 8 Homo sapiens 89-92 18189232-7 2008 RESULTS: 2-CADO pre-treatment followed by Docetaxel at subclinical dosage reduced the viability of either PC3 or LNCaP while it did not enhance Docetaxel-induced cytotoxicity in adherent non-neoplastic HECV. Docetaxel 42-51 chromobox 8 Homo sapiens 106-109 18189232-10 2008 CONCLUSIONS: Pretreatment of PC3 cells with 2-CADO decreased the effective concentration of Docetaxel, lowered the metastatic potential, and induced the production of cytokines known to stimulate the immune response against cancer. Docetaxel 92-101 chromobox 8 Homo sapiens 29-32 12439335-13 2002 The combination of docetaxel with an anthracycline was also synergistic in the two hormone-refractory cell lines, DU 145 and PC3, thus suggesting a potential role in advanced disease after endocrine failure. Docetaxel 19-28 chromobox 8 Homo sapiens 125-128 12222966-1 2002 We evaluated in vitro the effect of paclitaxel and docetaxel on PC-3 and DU-145 prostate cancer cell lines to understand better the downstream events in drug-induced tumor cell death. Docetaxel 51-60 chromobox 8 Homo sapiens 64-68 11182366-0 2001 Different docetaxel-induced apoptotic pathways are present in prostate cancer cell lines LNCaP and PC-3. Docetaxel 10-19 chromobox 8 Homo sapiens 99-103 11182366-1 2001 OBJECTIVES: To investigate the molecular machinery of docetaxel (Taxotere)-initiated death signaling on prostate cancer cell lines LNCaP and PC-3. Docetaxel 54-63 chromobox 8 Homo sapiens 141-145 11182366-1 2001 OBJECTIVES: To investigate the molecular machinery of docetaxel (Taxotere)-initiated death signaling on prostate cancer cell lines LNCaP and PC-3. Docetaxel 65-73 chromobox 8 Homo sapiens 141-145 11182366-4 2001 Taxotere has demonstrated induction of cell death in LNCaP and PC-3 cells. Docetaxel 0-8 chromobox 8 Homo sapiens 63-67 11182366-6 2001 METHODS: The prostate cancer cell lines, LNCaP and PC-3, were treated with 40 nM Taxotere for various lengths of time (0.5 to 24 hours). Docetaxel 81-89 chromobox 8 Homo sapiens 51-55 11182366-10 2001 CONCLUSIONS: In this study, we demonstrated two distinctly different Taxotere-induced apoptotic pathways in LNCaP and PC-3 cells that may be of clinical importance when treating prostate cancer. Docetaxel 69-77 chromobox 8 Homo sapiens 118-122 34190439-11 2021 In PC3 and DU145 cell lines, DRG2 knockdown increased docetaxel-induced Annexin V (+) apoptosis by 8.7 and 2.7 times, respectively. Docetaxel 54-63 chromobox 8 Homo sapiens 3-6 35152275-10 2022 LINC01963 silencing enhanced the chemosensitivity of PC3-DR to docetaxel and inhibited tumorigenicity and lung metastasis, while LINC01963 overexpression enhanced the chemoresistance of PC3 cells to docetaxel. Docetaxel 63-72 chromobox 8 Homo sapiens 53-56 35152275-10 2022 LINC01963 silencing enhanced the chemosensitivity of PC3-DR to docetaxel and inhibited tumorigenicity and lung metastasis, while LINC01963 overexpression enhanced the chemoresistance of PC3 cells to docetaxel. Docetaxel 63-72 chromobox 8 Homo sapiens 186-189 35152275-10 2022 LINC01963 silencing enhanced the chemosensitivity of PC3-DR to docetaxel and inhibited tumorigenicity and lung metastasis, while LINC01963 overexpression enhanced the chemoresistance of PC3 cells to docetaxel. Docetaxel 199-208 chromobox 8 Homo sapiens 53-56 35152275-15 2022 In conclusion, silencing LINC01963 inhibited TrkB protein level to enhance the chemosensitivity of PC3-DR to docetaxel by means of competitively binding to miR-216b-5p. Docetaxel 109-118 chromobox 8 Homo sapiens 99-102 33711972-0 2021 Sensitizing the cytotoxic action of Docetaxel induced by Pentoxifylline in a PC3 prostate cancer cell line. Docetaxel 36-45 chromobox 8 Homo sapiens 77-80 33711972-7 2021 METHODS: PC3 human prostate cancer cells were treated in vitro at different doses and times with PTX, DTX, or their combination. Docetaxel 102-105 chromobox 8 Homo sapiens 9-12 33711972-9 2021 RESULTS: We found that PTX in PC3 human prostate cancer cells induces significant apoptosis per se and increases that generated by DTX, while at the same time it reduces the senescence caused by the chemotherapy and increases caspases-3,-8, and -9 activity in PTX + DTX-treated cells. Docetaxel 131-134 chromobox 8 Homo sapiens 30-33 33711972-9 2021 RESULTS: We found that PTX in PC3 human prostate cancer cells induces significant apoptosis per se and increases that generated by DTX, while at the same time it reduces the senescence caused by the chemotherapy and increases caspases-3,-8, and -9 activity in PTX + DTX-treated cells. Docetaxel 266-269 chromobox 8 Homo sapiens 30-33